Sodium Nitroprusside Injection, Solution, Concentrate
NDC Package 70436-028-80

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Sodium Nitroprusside injection is sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. This formulation utilizes a injection, solution, concentrate delivery system. Marketed by Slate Run Pharmaceuticals, Llc, this product is identified by NDC 70436-028 and is authorized under FDA application ANDA214199.

Identification & Billing

NDC Package Code
70436-028-80
Package Description
1 VIAL in 1 CARTON / 2 mL in 1 VIAL
Product Code
70436-028
11-Digit Billing Format
70436002880
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Sodium Nitroprusside
Non-Proprietary Name
Sodium Nitroprusside
Substance Name
Sodium Nitroprusside
Dosage Form
Injection, Solution, Concentrate - A sterile preparation for parenteral use which, upon the addition of suitable solvents, yields a solution conforming in all respects to the requirements for Injections.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
SODIUM NITROPRUSSIDE 50 mg/2mL
Pharmacologic Class
Usage Information
Sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. Concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with sodium nitroprusside can be minimized.Sodium nitroprusside is also indicated for producing controlled hypotension in order to reduce bleeding during surgery.Sodium nitroprusside is also indicated for the treatment of acute congestive heart failure.

Regulatory & Marketing

Labeler Name
Slate Run Pharmaceuticals, Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA214199
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
10-15-2020
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70436-028-80 identifies a specific commercial package of 1 vial in 1 carton / 2 ml in 1 vial of Sodium Nitroprusside, a human prescription drug labeled by Slate Run Pharmaceuticals, Llc. This injection, solution, concentrate is formulated for intravenous use and contains sodium nitroprusside as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Slate Run Pharmaceuticals, Llc on October 15, 2020. The current certification is valid through December 31, 2026.

How is this Slate Run Pharmaceuticals, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70436002880. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
70436-028-80
11-Digit CMS (5-4-2)
70436-0028-80

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.